# A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease

> **NCT07419828** · PHASE3 · RECRUITING · sponsor: **Shandong Suncadia Medicine Co., Ltd.** · enrollment: 1978 (estimated)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** HRS-1780 tablets
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07419828
- **Lead sponsor:** Shandong Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-13
- **Primary completion:** 2030-04
- **Final completion:** 2030-05
- **Target enrollment:** 1978 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07419828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07419828, "A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07419828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*